Literature DB >> 27865102

Pharmacotherapy for residual excessive sleepiness and cognition in CPAP-treated patients with obstructive sleep apnea syndrome: A systematic review and meta-analysis.

Ariane B C C Avellar1, Luciane B C Carvalho2, Gilmar F Prado2, Lucila B F Prado3.   

Abstract

Pharmacotherapy has been used as an adjunct to CPAP for treatment of residual excessive sleepiness in patients with a diagnosis of obstructive sleep apnea syndrome (OSAS). However, no studies with a high level of evidence have been conducted to support this practice and confirm its effectiveness. We conducted a meta-analysis to summarize and quantify the effects of pharmacological treatment in adults with OSAS who experience residual excessive sleepiness despite adequate CPAP use. We reviewed clinical trials that compared medications to placebo and evaluated the outcomes residual excessive sleepiness, cognition, and quality of life, as well as treatment effectiveness and safety. The MEDLINE, EMBASE, LILACS, Cochrane Central Register of Controlled Trials - CENTRAL, and PsycINFO electronic databases were searched using highly sensitive search strategies. Trials were only included if measures were taken to ensure effective CPAP treatment. Eight randomized clinical trials were included. Pharmacotherapy with modafinil and armodafinil led to improvement of excessive daytime sleepiness, attention/alertness, and clinical condition as measured with the CGI-C. No improvements in quality of life or other cognitive domains (including memory, executive function, and language) could be confirmed. Pharmacotherapy did not cause any severe adverse effects, but was associated with significant dropout rates as compared with placebo. In conclusion, although our results demonstrate the effectiveness of pharmacological treatment as an adjunct to CPAP, further investigation is necessary to improve confidence in its effects. Many findings on the impact of pharmacotherapy on cognition and quality of life were evaluated through analysis of single studies, with heterogeneity in tests and absence of standardization, which reduced certainty as to whether actual improvement occurred in these outcomes.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CPAP; Cognition; Excessive sleepiness; Meta-analysis; Obstructive sleep apnea syndrome; Pharmacotherapy; Wakefulness

Mesh:

Year:  2015        PMID: 27865102     DOI: 10.1016/j.smrv.2015.10.005

Source DB:  PubMed          Journal:  Sleep Med Rev        ISSN: 1087-0792            Impact factor:   11.609


  8 in total

1.  Efficacy of THN102 (a combination of modafinil and flecainide) on vigilance and cognition during 40-hour total sleep deprivation in healthy subjects: Glial connexins as a therapeutic target.

Authors:  Fabien Sauvet; Mégane Erblang; Danielle Gomez-Merino; Arnaud Rabat; Mathias Guillard; Dominique Dubourdieu; Hervé Lefloch; Catherine Drogou; Pascal Van Beers; Clément Bougard; Cyprien Bourrrilhon; Pierrick Arnal; Werner Rein; Franck Mouthon; Francoise Brunner-Ferber; Damien Leger; Yves Dauvilliers; Mounir Chennaoui; Mathieu Charvériat
Journal:  Br J Clin Pharmacol       Date:  2019-09-15       Impact factor: 4.335

2.  Natural Cannabinoids as Templates for Sleep Disturbances Treatments.

Authors:  Eric Murillo-Rodríguez; Sérgio Machado; Claudio Imperatori; Tetsuya Yamamoto; Henning Budde
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Indirect treatment comparison of solriamfetol, modafinil, and armodafinil for excessive daytime sleepiness in obstructive sleep apnea.

Authors:  Sarah Ronnebaum; Morgan Bron; Dipen Patel; Diane Menno; Shay Bujanover; David Kratochvil; Eleanor Lucas; Carl Stepnowsky
Journal:  J Clin Sleep Med       Date:  2021-12-01       Impact factor: 4.062

Review 4.  Current and novel treatment options for obstructive sleep apnoea.

Authors:  Winfried Randerath; Jan de Lange; Jan Hedner; Jean Pierre T F Ho; Marie Marklund; Sofia Schiza; Jörg Steier; Johan Verbraecken
Journal:  ERJ Open Res       Date:  2022-06-27

5.  Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment. A Randomized Trial.

Authors:  Yves Dauvilliers; Johan Verbraecken; Markku Partinen; Jan Hedner; Tarja Saaresranta; Ognian Georgiev; Rumen Tiholov; Isabelle Lecomte; Renaud Tamisier; Patrick Lévy; Catherine Scart-Gres; Jeanne-Marie Lecomte; Jean-Charles Schwartz; Jean-Louis Pépin
Journal:  Am J Respir Crit Care Med       Date:  2020-05-01       Impact factor: 21.405

Review 6.  Paediatrics: how to manage obstructive sleep apnoea syndrome.

Authors:  Theresa Nh Leung; James Wch Cheng; Anthony Kc Chan
Journal:  Drugs Context       Date:  2021-03-26

7.  Relationship between sleep efficacy endpoints and measures of functional status and health-related quality of life in participants with narcolepsy or obstructive sleep apnea treated for excessive daytime sleepiness.

Authors:  Terri E Weaver; Susan D Mathias; Ross D Crosby; Morgan Bron; Shay Bujanover; Diane Menno; Kathleen F Villa; Christopher Drake
Journal:  J Sleep Res       Date:  2020-10-13       Impact factor: 3.981

8.  Excessive Daytime Sleepiness in Obstructive Sleep Apnea. Mechanisms and Clinical Management.

Authors:  Chitra Lal; Terri E Weaver; Charles J Bae; Kingman P Strohl
Journal:  Ann Am Thorac Soc       Date:  2021-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.